Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PPL Therapeutics -- Ignore unavailable to you. Want to Upgrade?

To: Jongmans who wrote (45)	10/17/2001 4:30:02 AM
From: nigel bates	Respond to of 53

From the rights announcement in March - "...PPL has recently been awarded a contract by DARPA for up to $3.1 million to support research involving the potential to produce large quantities of human polyclonal antibodies against a range of biological warfare agents, such as Anthrax and Ebola (amongst others). PPL retains the rights to commercialise all non-military applications of the technology, for example, in the potential treatment of diseases such as autoimmune disease, hepatitis, HIV and cancer..."